Drugs / Soluble beta-glucan
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01910597 | Aug 2013 → Apr 2016 | cancer | Prince of Songkla University | Completed | No outcome recorded |
| Phase 1 | NCT00533728 | Sep 2007 → Feb 2009 | non-Hodgkin lymphoma | Biotec Pharmacon ASA | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00632008 | Mar 2007 → Aug 2009 | ulcer of lower limbs | Biotec Pharmacon ASA | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Soluble Beta-Glucan | “Phase I, Dose-Escalation Study of Soluble Beta-Glucan (SBG) in Patients With Advanced Solid Tumors” NCT01910597 ↗ |
| Known as | SBG | “Soluble Beta-Glucan (SBG) is a compound prepared from commercial active dry Baker's yeast” NCT01910597 ↗ |
| Route | Topical | “Topical application of SBG to the wound” NCT00632008 ↗ |